Table 6.
Sensitivity analysis on incremental net benefits in pounds sterling
| Overall: two to five organ systems failing | Two organ systems failing | Three to five organ systems failing | |
|---|---|---|---|
| Base case | -5,934 (-12,735 to 868) | -34,031 (-47,028 to -21,034) | 5,690 (-2,543 to 13,924) |
| Pscore matching | -7,641 (-13,213, -2,069) | -32,846 (-44,704, -20,987) | 391 (-6,350, 7,133) |
| DrotAA given within 24 hoursa | 8,078 (733 to 15,423) | 11,131 (-2,173 to 24,435) | 12,387 (3,491 to 21,283) |
| Cost of drug (alternative assumption) | -4,687 (-11,544 to 2,171) | -33,232 (-46,309 to -20,154) | 7,339 (-976 to 15,653) |
| Excess mortality up to 25 years | -6,240 (-12,897 to 418) | -33,580 (-46,300 to -20,860) | 5,046 (-3,012 to 13,104) |
| Excess reduction in HRQOL up to 25 years | -7,240 (-13,328 to -1,152) | -31,895 (-43,509 to -20,280) | 2,863 (-4,512 to 10,237) |
| HRQOL of critical care survivors is 70% that of general population | -6,029 (-12,679 to 621) | -32,176 (-44,912 to -19,440) | 4,839 (-3,202 to 12,880) |
| HRQOL of critical care survivors is 90% that of general population | -5,347 (-12,254 to 1,560) | -33,134 (-46,353 to -19,915) | 6,239 (-2,117 to 14,596) |
Values are presented as mean (95% confidence interval). Incremental net benefits are calculated by multiplying the mean quality-adjusted life year gain (or loss) by £20,000 and subtracting from this the incremental cost. aOverall (two to five organ systems failing): total number = 2,337, Drotrecogin alfa (activated) (DrotAA) = 687, control = 1,650; two organ systems failing: total number = 727, DrotAA = 97, control = 630; three to five organ systems failing: total number = 1,610, DrotAA = 590, control = 1,020. HRQOL, health-related quality of life; Pscore, propensity score.